CoChat

Small Molecules Targeting Mutant P53: A Promising Approach for Cancer Treatment

Lopes, Elizabeth A., Gomes, Sara, Saraiva, Lucília, Santos, Maria M.M. · 2020 · Current Medicinal Chemistry
Cited by 14

The DOI matches its Crossref record, with a small difference in title or year; 17 of the 17 references it cites were found in a registry or an index.

Abstract

: More than half of all human tumors express mutant forms of p53, with the ovary, lung, pancreas, and colorectal cancers among the tumor types that display the highest prevalence of p53 mutations. In addition, the expression of mutant forms of p53 in tumors is associated with poor prognosis due to increased chemoresistance and invasiveness. Therefore, the pharmacological restoration of wild-type-like activity to mutant p53 arises as a promising therapeutic strategy against cancer. This review is focused on the most relevant mutant p53 small molecule reactivators described to date. Despite some of them have entered into clinical trials, none has reached the clinic, which emphasizes that new pharmacological alternatives, particularly with higher selectivity and lower adverse toxic side effects, are still required.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/0929867325666181116124308

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 68

  1. Bieging K.T.; Mello S.S.; Attardi L.D.; Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer 2014,14(5),359-370 · DOI · Paper page
  2. Vousden K.H.; Lane D.P.; p53 in health and disease. Nat Rev Mol Cell Biol 2007,8(4),275-283 · DOI · Paper page
  3. Zilfou J.T.; Lowe S.W.; Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol 2009,1(5) · DOI · Paper page
  4. Menendez D.; Inga A.; Resnick M.A.; Potentiating the p53 network. Discov Med 2010,10(50),94-100
  5. Vyas P.; Beno I.; Xi Z.; Stein Y.; Golovenko D.; Kessler N.; Rotter V.; Shakked Z.; Haran T.E.; Diverse p53/DNA binding modes expand the repertoire of p53 response elements. Proc Natl Acad Sci USA 2017,114(40),10624-10629 · DOI · Paper page
  6. Ribeiro C.J.; Rodrigues C.M.; Moreira R.; Santos M.M.; Chemical variations on the p53 reactivation theme. Pharmaceuticals (Basel) 2016,9(2),25 · DOI
  7. Lemos A.; Leão M.; Soares J.; Palmeira A.; Pinto M.; Saraiva L.; Sousa M.E.; Medicinal chemistry strategies to disrupt the p53-MDM2/MDMX interaction. Med Res Rev 2016,36(5),789-844 · DOI · Paper page
  8. Soares J.; Loureiro J.B.; Saraiva L.; Keeping p53 active: The challenge of cancer therapy. Advances in Drug Discovery and Development 2017
  9. Laptenko O.; Prives C.; Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ 2006,13(6),951-961 · DOI · Paper page
  10. Joerger A.C.; Fersht A.R.; Structural biology of the tumor suppressor p53. Annu Rev Biochem 2008,77,557-582 · DOI · Paper page
  11. Chan W.M.; Siu W.Y.; Lau A.; Poon R.Y.; How many mutant p53 molecules are needed to inactivate a tetramer? Mol Cell Biol 2004,24(8),3536-3551 · DOI · Paper page
  12. Chène P.; In vitro analysis of the dominant negative effect of p53 mutants. J Mol Biol 1998,281(2),205-209 · DOI
  13. Xu J.; Reumers J.; Couceiro J.R.; De Smet F.; Gallardo R.; Rudyak S.; Cornelis A.; Rozenski J.; Zwolinska A.; Marine J.C.; Lambrechts D.; Suh Y.A.; Rousseau F.; Schymkowitz J.; Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol 2011,7(5),285-295 · DOI · Paper page
  14. Di Como C.J.; Gaiddon C.; Prives C.; p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 1999,19(2),1438-1449 · DOI · Paper page
  15. Monti P.; Campomenosi P.; Ciribilli Y.; Iannone R.; Aprile A.; Inga A.; Tada M.; Menichini P.; Abbondandolo A.; Fronza G.; Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay. Oncogene 2003,22(34),5252-5260 · DOI
  16. Oren M.; Rotter V.; Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010,2(2) · DOI · Paper page
  17. Adorno M.; Cordenonsi M.; Montagner M.; Dupont S.; Wong C.; Hann B.; Solari A.; Bobisse S.; Rondina M.B.; Guzzardo V.; Parenti A.R.; Rosato A.; Bicciato S.; Balmain A.; Piccolo S.A.; Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009,137(1),87-98 · DOI · Paper page
  18. Bergamaschi D.; Gasco M.; Hiller L.; Sullivan A.; Syed N.; Trigiante G.; Yulug I.; Merlano M.; Numico G.; Comino A.; Attard M.; Reelfs O.; Gusterson B.; Bell A.K.; Heath V.; Tavassoli M.; Farrell P.J.; Smith P.; Lu X.; Crook T.; p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003,3(4),387-402 · DOI · Paper page
  19. Muller P.A.; Caswell P.T.; Doyle B.; Iwanicki M.P.; Tan E.H.; Karim S.; Lukashchuk N.; Gillespie D.A.; Ludwig R.L.; Gosselin P.; Cromer A.; Brugge J.S.; Sansom O.J.; Norman J.C.; Vousden K.H.; Mutant p53 drives invasion by promoting integrin recycling. Cell 2009,139(7),1327-1341 · DOI · Paper page
  20. Lawrence M.S.; Stojanov P.; Mermel C.H.; Robinson J.T.; Garraway L.A.; Golub T.R.; Meyerson M.; Gabriel S.B.; Lander E.S.; Getz G.; Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014,505(7484),495-501 · DOI · Paper page
  21. Ablain J.; Poirot B.; Esnault C.; Lehmann-Che J.; de Thé H.; p53 as an effector or inhibitor of therapy response. Cold Spring Harb Perspect Med 2015,6(1) · DOI · Paper page
  22. Lin C.H.; Chen I.C.; Huang C.S.; Hu F.C.; Kuo W.H.; Kuo K.T.; Wang C.C.; Wu P.F.; Chang D.Y.; Wang M.Y.; Chang C.H.; Chen W.W.; Lu Y.S.; Cheng A.L.; TP53 mutational analysis enhances the prognostic accuracy of IHC4 and PAM50 assays. Sci Rep 2015,5,17879 · DOI
  23. Lu C.; El-Deiry W.S.; Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis 2009,14(4),597-606 · DOI
  24. Pirollo K.F.; Bouker K.B.; Chang E.H.; Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs 2000,11(6),419-432 · DOI
  25. Zhou G.; Liu Z.; Myers J.N.; TP53 mutations in head and neck squamous cell carcinoma and their impact on disease progression and treatment response. J Cell Biochem 2016,117(12),2682-2692 · DOI · Paper page
  26. Lowe S.W.; Ruley H.E.; Jacks T.; Housman D.E.; p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993,74(6),957-967 · DOI · Paper page
  27. Parrales A.; Iwakuma T.; Targeting oncogenic mutant p53 for cancer therapy. Front Oncol 2015,5(288),288 · DOI · Paper page
  28. Mantovani F.; Walerych D.; Sal G.D.; Targeting mutant p53 in cancer: a long road to precision therapy. FEBS J 2017,284(6),837-850 · DOI · Paper page
  29. Foster B.A.; Coffey H.A.; Morin M.J.; Rastinejad F.; Pharmacological rescue of mutant p53 conformation and function. Science 1999,286(5449),2507-2510 · DOI · Paper page
  30. Luu Y.; Bush J.; Cheung K-J.; Li G.; The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway. Exp Cell Res 2002,276(2),214-222 · DOI
  31. Takimoto R.; Wang W.; Dicker D.T.; Rastinejad F.; Lyssikatos J.; el-Deiry W.S.; The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 2002,1(1),47-55 · DOI · Paper page
  32. Wang W.; Takimoto R.; Rastinejad F.; El-Deiry W.S.; Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 2003,23(6),2171-2181 · DOI · Paper page
  33. Rippin T.M.; Bykov V.J.; Freund S.M.; Selivanova G.; Wiman K.G.; Fersht A.R.; Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 2002,21(14),2119-2129 · DOI · Paper page
  34. Weinmann L.; Wischhusen J.; Demma M.J.; Naumann U.; Roth P.; Dasmahapatra B.; Weller M.; A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2008,15(4),718-729 · DOI
  35. Demma M.J.; Wong S.; Maxwell E.; Dasmahapatra B.; CP-31398 restores DNA-binding activity to mutant p53 in vitro but does not affect p53 homologs p63 and p73. J Biol Chem 2004,279(44),45887-45896 · DOI · Paper page
  36. Demma M.; Maxwell E.; Ramos R.; Liang L.; Li C.; Hesk D.; Rossman R.; Mallams A.; Doll R.; Liu M.; Seidel-Dugan C.; Bishop W.R.; Dasmahapatra B.; SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53. J Biol Chem 2010,285(14),10198-10212 · DOI · Paper page
  37. Bykov V.J.; Issaeva N.; Selivanova G.; Wiman K.G.; Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 2002,23(12),2011-2018 · DOI · Paper page
  38. Nahi H.; Lehmann S.; Mollgard L.; Bengtzen S.; Selivanova G.; Wiman K.G.; Paul C.; Merup M.; Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. Br J Haematol 2004,127(3),285-291 · DOI · Paper page
  39. Nahi H.; Merup M.; Lehmann S.; Bengtzen S.; Möllgård L.; Selivanova G.; Wiman K.G.; Paul C.; PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. Br J Haematol 2006,132(2),230-236 · DOI · Paper page
  40. Ali D.; Jönsson-Videsäter K.; Deneberg S.; Bengtzén S.; Nahi H.; Paul C.; Lehmann S.; APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells. Eur J Haematol 2011,86(3),206-215 · DOI · Paper page
  41. Liang Y.; Mafuvadze B.; Besch-Williford C.; Hyder S.M.; A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts. Breast Cancer (Dove Med Press) 2018,10,53-67 · DOI
  42. Bykov V.J.; Issaeva N.; Zache N.; Shilov A.; Hultcrantz M.; Bergman J.; Selivanova G.; Wiman K.G.; Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem 2005,280(34),30384-30391 · DOI · Paper page
  43. Saha M.N.; Chen Y.; Chen M.H.; Chen G.; Chang H.; Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents. Br J Cancer 2014,110(9),2224-2231 · DOI · Paper page
  44. Bou-Hanna C.; Jarry A.; Lode L.; Schmitz I.; Schulze-Osthoff K.; Kury S.; Bezieau S.; Mosnier J-F.; Laboisse C.L.; Acute cytotoxicity of MIRA-1/NSC19630, a mutant p53-reactivating small molecule, against human normal and cancer cells via a caspase-9-dependent apoptosis. Cancer Lett 2015,359(2),211-217 · DOI
  45. Zache N.; Lambert J.M.; Rökaeus N.; Shen J.; Hainaut P.; Bergman J.; Wiman K.G.; Bykov V.J.; Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol Oncol 2008,2(1),70-80 · DOI · Paper page
  46. Boeckler F.M.; Joerger A.C.; Jaggi G.; Rutherford T.J.; Veprintsev D.B.; Fersht A.R.; Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 2008,105(30),10360-10365 · DOI · Paper page
  47. Yu X.; Vazquez A.; Levine A.J.; Carpizo D.R.; Allele-specific p53 mutant reactivation. Cancer Cell 2012,21(5),614-625 · DOI · Paper page
  48. Yu X.; Blanden A.R.; Narayanan S.; Jayakumar L.; Lubin D.; Augeri D.; Kimball S.D.; Loh S.N.; Carpizo D.R.; Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism. Oncotarget 2014,5(19),8879-8892 · DOI · Paper page
  49. Yu X.; Blanden A.R.; Tsang A.; Zaman S.; Liu Y.; gilleran, J.; Bencivenga, A. F.; Kimball, S. D.; Loh, S. N.; Carpizo, D. R. Thiosemicarbazones functioning as zinc metallochaperones to reactivate mutant p53. Mol Pharmacol 2017,91(6),567-575 · DOI · Paper page
  50. Salim K.Y.; Maleki Vareki S.; Danter W.R.; Koropatnick J.; COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo. Oncotarget 2016,7(27),41363-41379 · DOI · Paper page
  51. Silver N.L.; Osman A.A.; Patel A.A.; Tanaka N.; Tang L.; Zhou G.; Myers J.N.; A novel third generation thiosemicarbazone, COTI-2, is highly effective in killing head and neck squamous cell carcinomas (HNSCC) bearing a variety of TP53 mutations. Intl J Rad Oncol Biol Phys Vol. 94(4), p. 942.2016 · doi:10.1016/j.ijrobp.2015.12.272
  52. Liu X.; Wilcken R.; Joerger A.C.; Chuckowree I.S.; Amin J.; Spencer J.; Fersht A.R.; Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res 2013,41(12),6034-6044 · DOI · Paper page
  53. Kuo Y-C.; Kuo P-L.; Hsu Y-L.; Cho C-Y.; Lin C-C.; Ellipticine induces apoptosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells. Life Sci 2006,78(22),2550-2557 · DOI
  54. Stiborová M.; Indra R.; Moserová M.; Frei E.; Schmeiser H.H.; Kopka K.; Phillips D.H.; Arlt V.M.; NADH: Cytochrome b5 reductase and cytochrome b5 can act as sole electron donors to human cytochrome P450 1A1-mediated oxidation and DNA adduct formation by benzo[a]pyrene. Chem Res Toxicol 2016,29(8),1325-1334 · DOI
  55. Peng Y.; Li C.; Chen L.; Sebti S.; Chen J.; Rescue of mutant p53 transcription function by ellipticine. Oncogene 2003,22(29),4478-4487 · DOI
  56. Ohashi M.; Oki T.; Overview oncologic, endocrine · doi:10.1517/13543776.6.12.1285
  57. Miller C.M.; McCarthy F.O.; Isolation, biological activity and synthesis of the natural product ellipticine and related pyridocarbazoles. RSC Advances 2012,2(24),8883-8918 · doi:10.1039/c2ra20584j
  58. Sugikawa E.; Hosoi T.; Yazaki N.; Gamanuma M.; Nakanishi N.; Ohashi M.; Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine. Anticancer Res 1999,19(4B),3099-3108
  59. Mizumoto K.; Sato N.; Kusumoto M.; Niiyama H.; Maehara N.; Nishio S.; Li Z.; Ogawa T.; Tanaka M.; Diverse effects of 9-hydroxyellipticine on the chemosensitivity of human pancreatic cancer cells harboring p53 mutations. Cancer Lett 2000,149(1-2),85-94 · doi:10.1016/s0304-3835(99)00345-6
  60. Paoletti C.; Le Pecq J-B.; Dat-Xuong N.; Juret P.; Garnier H.; Amiel J-L.; Rouesse J.; Antitumor activity, pharmacology, and toxicity of ellipticines, ellipticinium, and 9-hydroxy derivatives: preliminary clinical trials of 2-methyl-9-hydroxy ellipticinium (NSC 264-137). Cancer Chemo-and Immunopharmacology 1980,107-123 · DOI
  61. Stiborová M.; Černá V.; Moserová M.; Mrízová I.; Arlt V.M.; Frei E.; The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, hepatic cytochrome P450 reductase null (HRN™) mice and pure enzymes. Int J Mol Sci 2014,16(1),284-306 · DOI
  62. Wassman C.D.; Baronio R.; Demir Ö.; Wallentine B.D.; Chen C-K.; Hall L.V.; Salehi F.; Lin D-W.; Chung B.P.; Hatfield G.W.; Richard Chamberlin A.; Luecke H.; Lathrop R.H.; Kaiser P.; Amaro R.E.; Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. Nat Commun 2013,4,1407 · DOI · Paper page
  63. Punganuru S.R.; Madala H.R.; Venugopal S.N.; Samala R.; Mikelis C.; Srivenugopal K.S.; Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties. Eur J Med Chem 2016,107,233-244 · DOI
  64. Bauer M.R.; Joerger A.C.; Fersht A.R.; 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells. Proc Natl Acad Sci USA 2016,113(36),E5271-E5280 · DOI · Paper page
  65. Synnott N.C.; Bauer M.R.; Madden S.; Murray A.; Klinger R.; O’Donovan N.; O’Connor D.; Gallagher W.M.; Crown J.; Fersht A.R.; Duffy M.J.; Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007. Cancer Lett 2018,414,99-106 · DOI
  66. Soares J.; Raimundo L.; Pereira N.A.; Monteiro Â.; Gomes S.; Bessa C.; Pereira C.; Queiroz G.; Bisio A.; Fernandes J.; Gomes C.; Reis F.; Gonçalves J.; Inga A.; Santos M.M.M.; Saraiva L.; Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule. Oncotarget 2016,7(4),4326-4343 · DOI
  67. Selvendiran K.; Kuppusamy M.L.; Bratasz A.; Tong L.; Rivera B.K.; Rink C.; Sen C.K.; Kálai T.; Hideg K.; Kuppusamy P.; Inhibition of vascular smooth-muscle cell proliferation and arterial restenosis by HO-3867, a novel synthetic curcuminoid, through up-regulation of PTEN expression. J Pharmacol Exp Ther 2009,329(3),959-966 · DOI
  68. Madan E.; Parker T.M.; Bauer M.R.; Dhiman A.; Pelham C.J.; Nagane M.; Kuppusamy M.L.; Holmes M.; Holmes T.R.; Shaik K.; Shee K.; Kiparoidze S.; Smith S.D.; Park Y.A.; Gomm J.J.; Jones L.J.; Tomás A.R.; Cunha A.C.; Selvendiran K.; Hansen L.A.; Fersht A.R.; Hideg K.; Gogna R.; Kuppusamy P.; The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53. J Biol Chem 2018,293(12),4262-4276 · DOI

Cited by

See all 14

Metadata

Authors
Lopes, E. A., Gomes, S., Saraiva, L., & Santos, M. M. M.
Affiliations
  • Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
  • LAQV-REQUIMTE, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal
Venue
Current Medicinal Chemistry
Published
2020-01-08
Volume
26
Issue
41
Pages
7323-7336
ISSN
0929-8673
Cited by
14
References
17
Language
en
Funders
Foundation for Science and Technology (PTDC/QUI-QOR/29664/2017, PTDC/DTPFTO/1981/2014–POCI-01-0145-FEDER-016581, UID/DTP/04138/2019, UID/QUI/50006/2019, CEECIND/01772/2017, SFRH/BD/96189/2013, SFRH/BD/137544/2018)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Small Molecules Targeting Mutant P53: A Promising Approach for Cancer Treatment. https://app.cochat.ai/papers/10.2174/0929867325666181116124308
The paper
Lopes, E. A., Gomes, S., Saraiva, L., & Santos, M. M. M. (2020). Small Molecules Targeting Mutant P53: A Promising Approach for Cancer Treatment. Current Medicinal Chemistry. https://doi.org/10.2174/0929867325666181116124308

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.